Claims
- 1. An indole or 2,3-dihydro-indole derivative of the formula: any of its enantiomers or any mixture thereof, or an acid addition salt thereof, whereinX is —O— or —S—, or —CR4R5—; and Y is —CR6R7—,—CR6R7—CR8R9—, or —CR6═CR7—; or X and Y together form a group —CR4═CR5—, or —CR4═CR5—CR6R7—; Z is —O— or —S—; A is selected from a group of formula (II) and (IV) wherein the dotted lines mean an optional bond; R1, R2, R3, R12, R13, R14, R15, R16 and R17 are each independently selected from hydrogen, halogen, trifluoromethyl, alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, hydroxy, formyl, acyl, amino, alkylamino, dialkylamino, acylamino, alkoxycarbonylamino, aminocarbonylamino, alkylaminocarbonylamino, dialkylaminocarbonylamino, nitro and cyano; R4, R5, R6, R7, R8 and R9 are each independently selected from hydrogen and alkyl; and R11 is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, phenyl, naphthyl, phenylalkyl, acyl and formyl.
- 2. The compounds of claim 1 wherein Z is —O—.
- 3. The compounds of claim 1 wherein Z is —S—.
- 4. The compounds of claim 1 wherein A is a group of formula (II).
- 5. The compounds of claim 1 wherein A is a group of formula (IV).
- 6. The compounds of claim 2 wherein A is a group of formula (II).
- 7. The compounds of claim 2 wherein A is a group of formula (IV).
- 8. The compounds of claim 3 wherein A is a group of formula (II).
- 9. The compounds of claim 3 wherein A is a group of formula (IV).
- 10. The compounds of claim 1 wherein R4, R5, R6, R7, R8 and R9 are selected from hydrogen or methyl.
- 11. The compounds of claim 1 selected from the group consisting of6-Chloro-3-[2-[4-(2,2,5-trimethyl-2,3-dihydrobenzofuran-7-yl)piperidin-1-yl]ethyl]-1H-indole; 6-Chloro-3-[2-[4-(2,2,-dimethyl-2,3-dihydrobenzofuran-7-yl)piperidin-1-yl]ethyl]-1H-indole; 6-Chloro-3-[2-[4-(2,2,-dimethyl-2,3-dihydrobenzofuran-7-yl)-1,2,3,6-tetrahydro-1-pyridy]ethyl]-1H-indole; 3-[2-[4-(1,4-Benzodioxan-5-yl)-1,2,3,6-tetrahydropyridin-1-yl]ethyl]-5-chloro-1H-indole; 3-[2-[4-(1,4-Benzodioxan-5-yl)-1,2,3,6-tetrahydropyridin-1-yl]ethyl]-5-fluoro-1H-indole; 3-[2-[4-(1,4-Benzodioxan-5-yl)piperidin-1-yl]ethyl]-6-chloro-1H-indole; 3-[2-[4-(1,4-Benzodioxan-5-yl)piperidin-1-yl]ethyl]-5-chloro-1H-indole; 3-[2-[4-(1,4-Benzodioxan-5-yl)piperidin-1-yl]ethyl]-5-fluoro-1H-indole; 6-Chloro-3-[2-[4-(2,3-dihydrobenzofuran-7-yl)-1,2,3,6-tetrahydropyridin-1-yl]ethyl]-1H-indole; 3-[2-[4-(Benzofuran-7-yl-1,2,3,6-tetrahydropyridin-1-yl]ethyl]-6-chloro-1H-indole; 3-[2-[4-(Benzofuran-7-yl-1,2,3,6-tetrahydropyridin-1-yl]ethyl]-5-bromo-1H-indole; 3-[2-[4-(Benzofuran-7-yl-1,2,3,6-tetrahydropyridin-1-yl]ethyl]-5-fluoro-1H-indole; 3-[2-[4-(Benzofuran-7-yl)piperidin-1-yl]ethyl]-6-chloro-1H-indole; 3-[2-[4-(Benzofuran-7-yl)piperidin-1-yl]ethyl]-5-fluoro-1H-indole; 3-[2-[4-(1,4-Benzodioxan-5-yl)-1,2,3,6-tetrahydro-1-pyridyl]ethyl]-6-chloro-1H-indole: 3-[2-[4-(1,4-Benzodioxan-5-yl)-piperidin-1-yl]ethyl]-6-chloro-1H-indole; and 3-[2-[4-(Benzofuran-7-yl)piperidin-1-yl]ethyl]-5-bromo-1H-indole; or an acid addition salt thereof.
- 12. A method of treating a disorder or disease of a living animal body, said disorder or disease selected from the group consisting of an affective disorder, anxiety disorder, panic disorder and obsessive compulsive disorder, comprising administering to said living animal body a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable acid addition salt thereof.
- 13. An indole or 2,3-dihydro-indole derivative of the formula: any of its enantiomers or any mixture thereof, or an acid addition salt thereof, whereinX is —O— or —S—, or —CR4R5—; and Y is —CR6R7—CR8R9—, or —CR6═CR7—; or X and Y together toxin a group —CR4═CR5—, or —R4═CR5—CR6R7—; Z is —O— or —S—; provided that when X and Z are both O, then Y is —CR6R7—CR8R9— or CR6═CR7—; A is selected from a group of formula (II), (III) and (IV) wherein the dotted lines mean an optional bond; R1, R2, R3, R12, R13, R14, R15, R16 and R17 are each independently selected from hydrogen, halogen, trifluoromethyl, alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, hydroxy, formyl, acyl, amino, alkylamino, dialkylamino, acylamino, alkoxycarbonylamino, aminocarbonylamino, alkylaminocarbonylamino, dialkylaminocarbonylamino, nitro and cyano; R4, R5, R6, R7, R8 and R9 are each independently selected from hydrogen and alkyl; and R11 is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, phenyl, naphthyl, phenylalkyl, acyl and formyl.
- 14. The compounds of claim 13 wherein Z is —O—.
- 15. The compounds of claim 13 wherein Z is —S—.
- 16. The compounds of claim 13 wherein A is a group of formula (II).
- 17. The compounds of claim 13 wherein A is a group of formula (III).
- 18. The compounds of claim 13 wherein A is a group of formula (IV).
- 19. The compounds of claim 14 wherein A is a group of formula (II).
- 20. The compounds of claim 14 wherein A is a group of formula (III).
- 21. The compounds of claim 14 wherein A is a group of formula (IV).
- 22. The compounds of claim 15 wherein A is a group of formula (II).
- 23. The compounds of claim 15 wherein A is a group of formula (III).
- 24. The compounds of claim 15 wherein A is a group of formula (IV).
- 25. The compounds of claim 13 wherein R4, R5, R6, R7, R8 and R9 are selected from hydrogen or methyl.
- 26. A method of treating a disorder or disease of a living animal body, said disorder or disease selected from the group consisting of an affective disorder, an anxiety disorder, panic disorder and obsessive compulsive disorder, comprising administering to said living animal body a therapeutically effective amount of a compound of claim 13, or a pharmaceutically acceptable acid addition salt thereof.
Priority Claims (1)
| Number |
Date |
Country |
Kind |
| 0892/97 |
Jul 1997 |
DK |
|
Parent Case Info
This is a division, of application Ser. No. 09/491,204, filed Jan. 25, 2000 now U.S. Pat. No. 6,476,035 which is a continuation of International application no. PCT/DK98/00336, filed Jul. 20, 1998, which claims benefit under 35 U.S.C. §119(e) of U.S. provisional application No. 60/053,713, filed Jul. 25, 1997. Each of these prior applications is hereby incorporated herein by reference, in its entirety.
US Referenced Citations (6)
| Number |
Name |
Date |
Kind |
|
3412097 |
Corts |
Nov 1968 |
A |
|
5002948 |
Perregaard et al. |
Mar 1991 |
A |
|
5242925 |
Boettcher et al. |
Sep 1993 |
A |
|
5464834 |
Peglion et al. |
Nov 1995 |
A |
|
5532241 |
Böttcher et al. |
Jul 1996 |
A |
|
5693655 |
Bottcher et al. |
Dec 1997 |
A |
Foreign Referenced Citations (6)
| Number |
Date |
Country |
| 4414113 |
Oct 1995 |
DE |
| 0376607 |
Jul 1990 |
EP |
| 529462 |
Mar 1993 |
EP |
| 0574313 |
Dec 1993 |
EP |
| 9828290 |
Jul 1998 |
WO |
| 0043382 |
Jul 2000 |
WO |
Non-Patent Literature Citations (2)
| Entry |
| Grunder et al., Psychopharmacology, 1995, 117:472-478. |
| Bartoszyk et al., European Journal of Pharmacology, 1997, 322:147-153. |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/053713 |
Jul 1997 |
US |
Continuations (1)
|
Number |
Date |
Country |
| Parent |
PCT/DK98/00336 |
Jul 1998 |
US |
| Child |
09/491204 |
|
US |
Patent Grant
6727263
